RaoT.K., FilipponeE.J., NicastriA.D., LandesmanS.H., FrankE., ChenC.K., FriedmanE.A.Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med1984: 310: 669–73.
2.
PardoV., AldanaM., ColtonR.M.Glomerular lesions: The acquired immunodeficiency syndrome. Ann Intern Med1984; 101: 429–34.
3.
GardenswartzM.H., LernerC.W., SeligsonG.R., ZabetakisP.M., RotterdamH., TapperM.L.Renal disease in patients with AIDS: A clinicopathologic study. Clin Nephrol1984; 21: 197–204.
4.
KimmelP.L., BarisoniL., KoppJ.B.Pathogenesis and treatment of HIV-associated renal diseases: Lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med2003; 139: 214–26.
5.
WeinerN.J., GoodmanJ.W., KimmelP.L.The HIV-associated renal diseases: Current insight into pathogenesis and treatment. Kidney Int2003; 63: 1618–31.
6.
D'AgatiV., SuhJ.I., CarboneL.Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study. Kidney Int1989; 35: 1358–70.
7.
D'AgatiV., AppelG.B.Renal pathology of human immunodeficiency virus infection. Semin Nephrol1998; 18: 406–21.
8.
Mohananm. HIV-associated nephropathy: An urban epidemic. Semin Nephrol2001; 21: 394–402.
9.
US Renal Data System (USRDS).USRDS 2001 annual data reportBethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institiutes of Health, 2001.
10.
AhujaT.S., BoruckiM., FuntanillaM., ShahinianV., HollanderM., RajaramanS.Is the prevalence of HIV-associated nephropahthy decreasing?Am J Nephrol1999; 19; 655–9.
11.
ShahinianV., RajaramanS., BoruckiM., GradyJ., HollanderW.M., AhujaT.S.Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis2000; 35: 884–8.
12.
Centers for Disease Control and Prevention (CDC): HIV/AIDS Surveillance Report. Atlanta, 2001: pp. 5–35.
13.
AbbottK.C., HypoliteI., WelchP.G., AyodoaL.Y.Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol2001; 14: 377–83.
CantorS.E., KimmelP.L., BoschJ.P.Effect of race on expression of acquired immunodeficiency syndrome-associated nephropathy. Arch Intern Med1991; 151: 125–8.
16.
SelikR.M., ByersR.H.Jr., DworkinM.S.Trends in diseases reported on US death certificates that mentioned HIV infection 1987-1999. J Acquir Immune Defic Syndr2002; 29: 378–87.
17.
WinstonJ.A., KlotmanP.E.Are we missing an epidemic of HIV-associated nephropathy. J Am Soc Nephrol1991; 7: 1–7.
18.
KimmelP.L., BoschJ.P., VassalottiJ.A.Treatment of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol1998; 18: 446–58.
19.
KimmelP.L., MishkinG.J., UmanaW.O.Captopril and renal survival in patients with human immunodeficiency viral nephropathy. Am J Kidney Dis1996; 28: 202–8.
20.
WattersonM.K., DetwilerR.K., BolinP.Jr.. Clinical response to prolonged corticosteroids in a patient with human immunodeficiency virus-associated nephropathy. Am J Kidney Dis1997; 29: 624–6.
21.
MattanaJ., SiegalF.P., SchwarzwaldE., MolkoL., SankaranR.T.AIDS-associated membranous nephropathy with advanced renal failure: Response to prednisone. Am J Kidney Dis1997; 30: 116–9.
22.
BurnsG.C., PaulS.K., TothI.R., SivakS.L.Effect of angiotensin-converting enzyme inhibors in HIV-associated nephropathy. J Am Soc Nephrol1997; 8: 1140–6.
23.
SinghA., TejaniC., TejaniA.One-center experience with cyclosporin in refractory nephrotic syndrome in children. Pediatr Nephrol1999; 13: 26–32.
24.
WaliR.K., DrachenberyC.L., PapadimitriouJ.C., KeayS., RamosE.HIV-associated nephropathy and response to highly active antiretroviral therapy. Lancet1998; 352: 783–4.
25.
AhujaT.S., BoruckiM., GradyJ.Highly active antiretroviaral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis2000; 36: 574–80.
KoppJ.B., MillerK.D., MicanJ.A., FenersteinJ.M., VaughanE., BakerC., PannellL.K., FalloonJ.Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med1997; 128: 1122–8.
28.
ReiterW.J., Schon-PernerstorferH., DorfingerK., HofbauerJ., MarbergerM.Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol1999; 161: 1082–4.
29.
VerhelstD., MongeM., MeynardJ.L., FouquerayB., MougenotB., GrirardP.M., RoncoP., RossertJ.Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis2002; 40: 1331–3.
30.
SchaafB., AriesP., KrammeE., DalhoffK.Acute renal failure associated with tenofivir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis2003; 37: 41–3.
31.
RaoT.K., FriedmanE.A., NicastriA.D.The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med1987; 316: 1062–8.
32.
OrtizC., MenesesR., JaffeD.Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int1988; 34: 248–53.
33.
DaveM.B., ShabihK., BlumS.Maintenance hemodialysis in patients with HIV-associated nephropathy. Clin Nephrol1996; 50: 367–74.
34.
KimmelP.L., UmanoW.O., SimmensS.J.Continuous ambulatory peritoneal dialysis and survival in HIV-infected patients with end-stage renal disease. Kidney Int1993; 44: 373–8.
35.
PerinbasekarS., Brod-MillerC., PalS., MattanaJ.Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol1996; 16: 280–6.
36.
MazarS.A., SchoenfeldP.Y., HumphreysM.H.Renal involvement in patients infected with HIV: Experience at San Francisco General Hospital. Kidney Int1990; 37: 1325–30.
37.
SzezechL.A., KalayjianR., RodriguezR., GuptaS., ColadonatoJ., WinstonJ.for the Adult AIDS Clinical Trial Group Renal Complications Committee. The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. Kidney Int2003; 63: 2295–301.
38.
BingelM., LonnemannG., KochR.M.Plasma interleukin-1 activity during hemodialysis: The influence of dialysis membrane. Nephron1988; 50: 273–6.
39.
HerbelinA., NguyenA.T., ZingraffJ.Infuence of uremia and hemodialysis on circulation interleukin-1 and tumor necrosis factor. Kidney Int1990; 37: 116–25.
40.
TakahashiT., KubotaM., NakamuraT., EbikaraI., KoideH.Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail2000; 22: 345–54.
41.
PoliG., BresslerP., KinterA., DuhE., TimmerW.C., RabsanA., JusterneatJ.S., StanleyS., FauciA.S.Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and ost-transcriptional mechanisms. J Exp Med1990; 172: 151–8.
42.
BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol1995; 6: 177–83.
43.
FentonS.A., SchaubelD.E., DesmeulesM.Hemodialysis vs peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis1997; 30: 334–42.
44.
VoneshE.F., MoranJ.Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol1999; 10: 354–65.
45.
CollinsA.J., WenliH., XiaH.Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis1999; 34: 1065–74.
46.
KimmelP.L., UmanaW.O., SimensS.J., WatsonJ., BoschJ.P.Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. Kidney Int1999; 44: 373–8.
47.
AhujaT.S., CollingeN., GradyJ., KhanS.Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy?Am J Kidney Dis2003; 41: 1060–4.
48.
MurphyB., CarlsonL., RohalS., KellerM., LuA., KumarM.S., GoldM., DamaskA., LightJ.W., StockP., RolandM.E.Abstract: Renal transplantation in HIV-infected recipients: Twenty-three cases in the HAART-era (Abstract). J Am Soc Nephrol2002; 13: 74P.
